Literature DB >> 26006092

Various forms of (18)F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica.

Zdenek Rehak1,2, Jiri Vasina1,3, Petr Nemec4, Zdenek Fojtik5, Renata Koukalova1, Zbynek Bortlicek6, Dorota Rehakova7, Jan Adam2,8, Alena Vavrusova9, Zdenek Adam5.   

Abstract

AIM: Polymyalgia rheumatica (PMR) is a disease presenting with pain and stiffness, mainly in shoulders, hip joints and neck. Laboratory markers of inflammation may bolster diagnosis. PMR afflicts patients over 50 years old, predominantly women, and may also accompany giant cell arteritis. PATIENTS AND METHODS: 67 patients, who fullfiled Healey´s criteria for PMR in the period between 2004 and 2013 and had positive FDG PET (PET/CT) findings were retrospectively evaluated. FDG uptake was assessed in large arteries, proximal joints (shoulders, hips and sternoclavicular joints), in extraarticular synovial structures (interspinous, ischiogluteal and praepubic bursae).
RESULTS: Articular/periarticular involvement (A) was detected in 59/67 (88.1%) patients and extrarticular synovial involvement (E) in 51/67 (76.1%) patients either individually or in combinations. Vascular involvement (V) was detected in 27/67 (40.3%) patients only in combination with articular (A) and/or extraarticular synovial (E) involvement. These combinations were: A+E involvement in 30/67 (44.8%) patients, A+V involvement in 8/67 (11.9%) patients, E+V involvement in 6/67 (9%) patients and A+E+V in 13/67 (19.4%) patients.
CONCLUSIONS: PMR presents by articular/periarticular synovitis, extraarticular synovitis and can be accompanied by giant cell arteritis. All types of involvement have their distinct FDG PET (PET/CT) finding, which can be seen either individually or in any of their 4 combinations. FDG PET (PET/CT) examination seems to be an advantageous one-step examination for detecting different variants of PMR, for assessing extent and severity and also for excluding occult malignancy.

Entities:  

Keywords:  FDG; PET; PET/CT; bursitis; giant cell arteritis; polymyalgia rheumatica; synovitis; vasculitis

Mesh:

Substances:

Year:  2015        PMID: 26006092     DOI: 10.5507/bp.2015.026

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  5 in total

Review 1.  18F-FDG PET/CT in polymyalgia rheumatica-a pictorial review.

Authors:  Zdenek Rehak; Andrea Sprlakova-Pukova; Tomas Kazda; Zdenek Fojtik; Lenka Vargova; Petr Nemec
Journal:  Br J Radiol       Date:  2017-06-16       Impact factor: 3.039

Review 2.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

3.  PET/CT imaging in polymyalgia rheumatica: praepubic 18F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis.

Authors:  Zdenek Rehak; Andrea Sprlakova-Pukova; Zbynek Bortlicek; Zdenek Fojtik; Tomas Kazda; Marek Joukal; Renata Koukalova; Jiri Vasina; Jana Eremiasova; Petr Nemec
Journal:  Radiol Oncol       Date:  2017-01-14       Impact factor: 2.991

Review 4.  Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient.

Authors:  Marcin Milchert; Marek Brzosko
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

Review 5.  FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC.

Authors:  Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-11       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.